EI

271.8

-0.77%↓

MRK1

107.4

+0.94%↑

SAN

79.42

+0.04%↑

SHL.DE

47.47

-0.63%↓

UCB

204.2

+0.25%↑

EI

271.8

-0.77%↓

MRK1

107.4

+0.94%↑

SAN

79.42

+0.04%↑

SHL.DE

47.47

-0.63%↓

UCB

204.2

+0.25%↑

EI

271.8

-0.77%↓

MRK1

107.4

+0.94%↑

SAN

79.42

+0.04%↑

SHL.DE

47.47

-0.63%↓

UCB

204.2

+0.25%↑

EI

271.8

-0.77%↓

MRK1

107.4

+0.94%↑

SAN

79.42

+0.04%↑

SHL.DE

47.47

-0.63%↓

UCB

204.2

+0.25%↑

EI

271.8

-0.77%↓

MRK1

107.4

+0.94%↑

SAN

79.42

+0.04%↑

SHL.DE

47.47

-0.63%↓

UCB

204.2

+0.25%↑

Search

Laboratorios Farmaceuticos Rovi SA

Închisă

SectorSănătate

59.35 0.08

Rezumat

Modificarea prețului

24h

Curent

Minim

58.95

Maxim

59.55

Indicatori cheie

By Trading Economics

Venit

3.9M

27M

Vânzări

4.8M

160M

P/E

Medie Sector

23.127

35.293

EPS

0.423

Randament dividend

1.54

Marjă de profit

16.767

Angajați

2,188

EBITDA

4.2M

35M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+34.97% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

1.54%

3.07%

Următoarele câștiguri

6 nov. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

242M

3.1B

Deschiderea anterioară

59.27

Închiderea anterioară

59.35

Sentimentul știrilor

By Acuity

56%

44%

317 / 371 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Weak Bullish Evidence

Laboratorios Farmaceuticos Rovi SA Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

17 sept. 2025, 23:01 UTC

Achiziții, Fuziuni, Preluări

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid -- Update

17 sept. 2025, 22:48 UTC

Achiziții, Fuziuni, Preluări

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid

17 sept. 2025, 21:59 UTC

Câștiguri

Cryptocurrency-Exchange Bullish Swings to Profit in First Report as Public Company

17 sept. 2025, 23:44 UTC

Market Talk

Nikkei May Rise as Yen Weakens -- Market Talk

17 sept. 2025, 23:39 UTC

Market Talk

Gold Rises Amid Prospects of Further Fed Rate Cuts -- Market Talk

17 sept. 2025, 22:20 UTC

Achiziții, Fuziuni, Preluări

Santos: XRG Consortium Wouldn't Agree to Appropriate Risk Allocation Between It and Santos Shareholders

17 sept. 2025, 22:20 UTC

Achiziții, Fuziuni, Preluări

Santos: XRG Consortium Wouldn't Agree to Acceptable Terms That Protected Value of Transaction

17 sept. 2025, 22:20 UTC

Achiziții, Fuziuni, Preluări

Santos Had Expressed Concern to XRG Consortium About Delays in Agreeing to Scheme Implementation Agreement

17 sept. 2025, 22:19 UTC

Achiziții, Fuziuni, Preluări

Santos: Consortium Notified Board of Decision to Withdraw Proposal on Weds Evening

17 sept. 2025, 22:18 UTC

Achiziții, Fuziuni, Preluări

Santos Confirms XRG Consortium Has Withdrawn Takeover Proposal

17 sept. 2025, 21:00 UTC

Câștiguri

Darden Restaurants to Report Earnings. Why the Olive Garden Parent Is Expected to Stay Strong. -- Barrons.com

17 sept. 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

17 sept. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

17 sept. 2025, 19:59 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 sept. 2025, 19:59 UTC

Market Talk

Treasury Yields, Dollar Rise as Fed Cuts, Powell Warns of Risks -- Market Talk

17 sept. 2025, 19:07 UTC

Market Talk

Oil Futures Snap Three-Session Winning Streak -- Market Talk

17 sept. 2025, 18:43 UTC

Market Talk

Treasury Yields, Dollar Reverse Course as Powell Talks to Reporters -- Market Talk

17 sept. 2025, 18:38 UTC

Market Talk

U.S. Natural Gas Futures Mixed Ahead of Storage Data -- Market Talk

17 sept. 2025, 18:20 UTC

Market Talk

Gold Dips After Quarter-Point Rate Cut -- Market Talk

17 sept. 2025, 18:18 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 sept. 2025, 18:18 UTC

Market Talk

Treasury Yields, Dollar Fall on Nearly Unanimous Fed Cut -- Market Talk

17 sept. 2025, 18:14 UTC

Market Talk

Oil Slips Some More as Fed Makes Expected 25 Bp Rate Cut -- Market Talk

17 sept. 2025, 17:59 UTC

Market Talk

Soyoil Takes Hit as Traders Consider EPA Proposal -- Market Talk

17 sept. 2025, 17:15 UTC

Achiziții, Fuziuni, Preluări

Netflix 'Has Won The Streaming Wars,' Analyst Says. The Stock Is a Buy. -- Barrons.com

17 sept. 2025, 17:06 UTC

Achiziții, Fuziuni, Preluări

Walmart Stock Heads for a Record High. The Retailer Could Become a Leader in 'Agentic' AI. -- Barrons.com

17 sept. 2025, 16:51 UTC

Câștiguri

Correct: Exor 1H Net Loss -EUR624M

17 sept. 2025, 16:34 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 sept. 2025, 16:34 UTC

Market Talk

Bank of Canada Ditches Resilience Talk, Plays Up Slowing Growth -- Market Talk

17 sept. 2025, 16:25 UTC

Câștiguri

Wolters Kluwer: July, August Saw a Slight Increase in Organic Growth Compared to 1H

17 sept. 2025, 16:23 UTC

Câștiguri

Wolters Kluwer: Year-to-Date Performance In Line With 2025 Guidance

Comparație

Modificare preț

Laboratorios Farmaceuticos Rovi SA Așteptări

Obiectiv de preț

By TipRanks

34.97% sus

Prognoză pe 12 luni

Medie 80.85 EUR  34.97%

Maxim 90 EUR

Minim 71.7 EUR

În baza a 2 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruLaboratorios Farmaceuticos Rovi SA - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

2 ratings

2

Cumpărare

0

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

51.1 / N/ASuport & Rezistență

Termen scurt

Weak Bullish Evidence

Termen mediu

Strong Bullish Evidence

Termen lung

Weak Bearish Evidence

Sentiment

By Acuity

317 / 371 Clasament în Sănătate

Sentimentul știrilor

Evidențe de scădere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.
help-icon Live chat